Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
H Akamatsu, N Katakami, I Okamoto, T Kato… - Cancer …, 2018 - Wiley Online Library
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI s) are the first‐line
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
H Akamatsu, N Katakami, I Okamoto, T Kato… - Cancer …, 2018 - europepmc.org
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI s) are the first‐line
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
H Akamatsu, N Katakami, I Okamoto… - Cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first-line
treatment for patients with EGFR mutant non-small-cell lung cancer (NSCLC). However …
treatment for patients with EGFR mutant non-small-cell lung cancer (NSCLC). However …
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
H Akamatsu, N Katakami, I Okamoto… - Cancer …, 2018 - repository.kulib.kyoto-u.ac.jp
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first‐line
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA 3 trial
H Akamatsu, N Katakami, I Okamoto, T Kato… - Cancer …, 2018 - search.proquest.com
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI s) are the first‐line
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
H Akamatsu, N Katakami, I Okamoto… - Cancer …, 2018 - kyushu-u.elsevierpure.com
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first-line
treatment for patients with EGFR mutant non-small-cell lung cancer (NSCLC). However …
treatment for patients with EGFR mutant non-small-cell lung cancer (NSCLC). However …
[PDF][PDF] Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
H Akamatsu, N Katakami, I Okamoto, T Kato, YH Kim… - Cancer science, 2018 - core.ac.uk
Epidermal growth factor receptor TKIs are established as the first line of treatment of patients
with EGFR-mutated NSCLC. 1 However, resistance nearly always develops. Despite good …
with EGFR-mutated NSCLC. 1 However, resistance nearly always develops. Despite good …
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
金永学 - Cancer science, 2018 - cir.nii.ac.jp
抄録 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first‐
line treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
line treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
[HTML][HTML] Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
H Akamatsu, N Katakami, I Okamoto, T Kato… - Cancer …, 2018 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI s) are the first‐line
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
H Akamatsu, N Katakami, I Okamoto, T Kato… - Cancer …, 2018 - europepmc.org
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI s) are the first‐line
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …